Dachaigh › Luchd-obrach › Crystal Pharmatech Inc.
Crystal Pharmatech Inc.: Tuarastalan H-1B agus taic bhìosa
Chuir Crystal Pharmatech Inc. 14 iarrtasan cumha-obrach a-steach airson bhìosaichean H-1B agus bhìosaichean co-cheangailte ann am bliadhnaichean ionmhais 2023–2026; le teisteanas: 14. Tuarastal meadhanach a chaidh a thabhann: $85,000.
A bheil Crystal Pharmatech Inc. a’ toirt taic do bhìosaichean H-1B?
Chuir Crystal Pharmatech Inc. 14 iarrtasan cumha-obrach a-steach ann am bliadhnaichean ionmhais 2023–2026, an tè as ùire air a chur a-steach air 26 Cèit 2026. Is e LCA a’ chiad cheum ann an iarrtas H-1B, mar sin tha an neach-fastaidh air taic a thoirt do luchd-obrach H-1B no air ullachadh airson sin a dhèanamh; cha gharantaich e taic airson dreuchd shònraichte sam bith. Thoir sùil air liostaichean obrach an neach-fastaidh fhèin.
Tuarastalan a rèir tiotal obrach
| Tiotal dreuchd | LCAs | Tuarastal meadhanach |
|---|---|---|
| Research Scientist II | 2 | $81,238 |
| Senior Research Scientist II | 1 | $160,000 |
| Senior Scientist I | 1 | $105,000 |
| Senior Human Resources Specialist | 1 | $85,000 |
| Human Resources Manager | 1 | $85,000 |
| Senior Research Scientist I | 1 | $96,000 |
| Research Scientist I | 1 | $78,000 |
| Business Operations Specialist | 1 | $58,000 |
| Operations Analyst | 1 | $55,000 |
| Research Scientist | 1 | $75,000 |
| Senior Scientist | 1 | $105,000 |
| Operations Assistant | 1 | $58,302 |
| Principal Scientist, Team Lead | 1 | $140,000 |
Iarrtasan a rèir bliadhna ionmhais
| Bliadhna mhaoine | LCAs | Tuarastal meadhanach |
|---|---|---|
| FY2023 | 7 | $85,000 |
| FY2024 | 4 | $66,500 |
| FY2026 | 3 | $85,476 |
Ìrean tuarastail làithreach
Suidhichidh Roinn an Obrach ceithir ìrean tuarastail làithreach airson gach dreuchd agus sgìre, bho Ìre I (inntrigeadh) gu Ìre IV (gu tur comasach). Taghaidh an neach-fastaidh an ìre a fhreagras ri riatanasan na h-obrach.
Far a bheil na h-obraichean
Dreuchdan
- Chemists8
- Business Operations Specialists, All Other3
- Human Resources Specialists2
- Biochemists and Biophysicists1
Iarrtasan as ùire
| Tiotal dreuchd | Tuarastal bunasach | Àite | Air a chur a-steach | Ceann-latha tòiseachaidh | Inbhe |
|---|---|---|---|---|---|
| Principal Scientist, Team Lead | $140,000 Ìre IV | Cranbury, NJ | 26 Cèit 2026 | 1 Dàmh 2026 | Dearbhaichte |
| Research Scientist II | $85,476 Ìre II | Cranbury, NJ | 1 Cèit 2026 | 1 Dàmh 2026 | Dearbhaichte |
| Operations Assistant | $58,302 Ìre I | Cranbury, NJ | 14 Gibl 2026 | 1 Dàmh 2026 | Dearbhaichte |
| Business Operations Specialist | $58,000 Ìre I | Cranbury, NJ | 6 Ògmh 2024 | 1 Dàmh 2024 | Dearbhaichte |
| Operations Analyst | $55,000 Ìre I | Cranbury, NJ | 14 Cèit 2024 | 1 Dàmh 2024 | Dearbhaichte |
| Senior Scientist | $105,000 Ìre III | Cranbury, NJ | 10 Cèit 2024 | 1 Dàmh 2024 | Dearbhaichte |
| Research Scientist | $75,000 Ìre I | Cranbury, NJ | 10 Cèit 2024 | 1 Dàmh 2024 | Dearbhaichte |
| Research Scientist I | $78,000 Ìre I | Cranbury, NJ | 17 Lùna 2023 | 1 Dàmh 2023 | Dearbhaichte |
| Senior Scientist I | $105,000 Ìre II | Cranbury, NJ | 6 Ògmh 2023 | 1 Dàmh 2023 | Dearbhaichte |
| Senior Human Resources Specialist | $85,000 Ìre II | Cranbury, NJ | 1 Cèit 2023 | 22 Cèit 2023 | Dearbhaichte |
| Human Resources Manager | $85,000 Ìre II | Cranbury, NJ | 24 Gibl 2023 | 22 Cèit 2023 | Dearbhaichte |
| Research Scientist II | $77,000 Ìre I | Cranbury, NJ | 12 Gibl 2023 | 1 Dàmh 2023 | Dearbhaichte |
| Senior Research Scientist I | $96,000 Ìre II | Cranbury, NJ | 5 Gibl 2023 | 1 Dàmh 2023 | Dearbhaichte |
| Senior Research Scientist II | $160,000 Ìre IV | Cranbury, NJ | 3 Dàmh 2022 | 24 Dàmh 2022 | Dearbhaichte |
Is e na tuarastalan an ìre as ìsle den tuarastal a chaidh a thabhann air gach iarrtas, air an tionndadh gu suim bhliadhnail; cleachdaidh na staitistigean iarrtasan làn-aimsire le teisteanas a-mhàin. Chan eil LCA na aontachadh bhìosa agus faodaidh aon LCA còmhdach a dhèanamh air iomadh dreuchd. Stòr: Roinn an Obrach na SA, Dàta Foillseachaidh OFLC LCA, bliadhnaichean ionmhais 2023–2026 (co-dhùnadh as ùire 30 Ògmh 2026).